Meda: Onsolis receives FDA approval
“The interest among specialists for this new technology is significant, and we are making preparations for product launch during the fourth quarter of 2009. The registration procedures for Onsolis in other key markets are progressing according to plan”, said Anders Lönner, CEO Meda.
Meda has, in close collaboration with the FDA and Meda’s development partner BioDelivery Sciences Inc, developed the REMS (Risk Evaluation and Mitigation Strategy) program for Onsolis. This REMS program has also been approved by the FDA.
Most read news
Other news from the department research and development
These products might interest you
Hydrosart® Ultrafilter by Sartorius
Efficient ultrafiltration for biotech and pharma
Maximum flow rates and minimum protein loss with Hydrosart® membranes
Hydrosart® Microfilter by Sartorius
Hydrophilic microfilters for bioprocesses
Minimal protein adsorption and high flow rates
Polyethersulfone Microfilter by Sartorius
Biotechnological filtration made easy
Highly stable 0.1 µm PESU membranes for maximum efficiency
Sartobind® Rapid A by Sartorius
Efficient chromatography with disposable membranes
Increase productivity and reduce costs with fast cycle times
Sartopore® Platinum by Sartorius
Efficient filtration with minimal protein adsorption
Reduces rinsing volume by 95 % and offers 1 m² filtration area per 10"
Polyethersulfone Ultrafilter by Sartorius
Reliable filtration with PESU membranes
Perfect for biotechnology and pharmaceuticals, withstands sterilisation and high temperatures
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.